We are pleased to inform you that Biomnis’ services have been selected by the UNICANCER hospital group for the Prosigna® beast cancer prognostic gene signature assay.

In practice, in addition to a research program on therapeutic practices associated with genomic tests, Biomnis has been offering the Prosigna® genomic assay for the Centres de Lutte Contre Le Cancer which make up the UNICANCER group since December.

This Prosigna® gene expression test for breast cancer prognosis has been developed based on the PAM 50 gene signature for tumours in the breast parenchyma. This molecular signature is defined by the level of expression of 50 different genes in cancerous cells and makes it possible to asses the risk of distant tumour recurrence for a given patient.

The Prosigna® assay thus enables individualized and personalized management of breast cancer when treatment decisions are hard to make, by identifying patients for whom chemotherapy should be prescribed, and avoiding other treatments without any benefits.